A study of the effects of buspirone, BMY 13805, and 1-PP on dopaminergic metabolism in the nucleus accumbens using in vivo voltammetry in freely moving rats.
The effects of buspirone, a buspirone analogue (BMY 13805) and a buspirone metabolite (1-PP) on dopaminergic metabolism in the nucleus accumbens were investigated using in vivo voltammetry. Differential pulse voltammetry coupled with electrochemically pretreated carbon fiber electrodes was used to provide a continuous and selective measure of the 3,4-dihydroxyphenylacetic acid (DOPAC). An implanted micromanipulator enabled the use of freely moving animals. Buspirone injections induced a marked and rapid increase of the DOPAC peak in the nucleus accumbens. Buspirone was 10 times more potent when injected subcutaneously than intraperitoneally. BMY 13805 and 1-PP were without effect on dopaminergic metabolism in the nucleus accumbens. In conclusion, the anxiolytic properties of these drugs and their effects on dopaminergic metabolism do not appear related.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002065:Buspirone / Q000031:analogs & derivatives; D004298:Dopamine / Q000378:metabolism*; D004563:Electrochemistry; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012686:Septal Nuclei / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D010879:Piperazines; D011743:Pyrimidines; D015102:3,4-Dihydroxyphenylacetic Acid; C037921:1-(2-pyrimidinyl)piperazine; C039979:gepirone; D002065:Buspirone; D004298:Dopamine